Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk

Chrystal Landry, MD, Dory Londono, Sean M. Devlin, PhD, Alex Lesokhin, MD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, David J Chung, MD PhD, Guenther Koehne, MD, PhD, Suresh C. Jhanwar, PhD, Sergio A Giralt, MD, Heather Landau, MD

Blood (2013) 122 (21): 1910.

https://doi.org/10.1182/blood.V122.21.1910.1910

Published: 2013

Journal Articles

Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

Lionel Karlin, David Ghez, Marie-Olivia Chandesris, Sylvain Choquet, Margaret Macro, Didier Bouscary, Sophie Cereja, Marion Malphettes, Bouchra Asli, Vincent Levy, Jean Soulier, Jean-Paul Fermand, Bertrand Arnulf

Blood (2009) 114 (22): 3408.

https://doi.org/10.1182/blood.V114.22.3408.3408

Published: 2009

Journal Articles

A Prospective Study of t(4;14) Multiple Myeloma.

Lionel Karlin, MD, David Ghez, MD, Sylvain Choquet, MD, PhD, Karim Belhadj, MD, Margaret Macro, MD, Didier Bouscary, MD, PhD, Jean Soulier, MD, PhD, Raphael Porcher, PhD, Marion Malphettes, MD, Bouchra Asli, MD, Jean-Claude Brouet, MD, PhD, Jean-Paul Fermand, MD, PhD, Bertrand Arnulf, MD, PhD

Blood (2007) 110 (11): 414.

https://doi.org/10.1182/blood.V110.11.414.414

Published: 2007

Journal Articles

Proline-Rich Tyrosine Kinase-2 (PYK2): A New Target for the Treatment of Hematopoietic Neoplasms with TEL-FGFR3 Fusion or FGFR3 Active Mutation.

Daisuke Okamura, Fumiharu Yagasaki, Tomoya Maeda, Maho Ishikawa, Itsuro Jinnai, Masami Bessho

Blood (2007) 110 (11): 3360.

https://doi.org/10.1182/blood.V110.11.3360.3360

Published: 2007

Journal Articles

Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.

Esther Masih-Khan, Suzanne Trudel, MD, ZhiHua Li, Vincent Nadeem, Ellen Wei, Joshua Paterson, Jaime O. Claudio, A. Keith Stewart, MD

Blood (2005) 106 (11): 251.

https://doi.org/10.1182/blood.V106.11.251.251

Published: 2005

NARROW

Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk

Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

A Prospective Study of t(4;14) Multiple Myeloma.

Proline-Rich Tyrosine Kinase-2 (PYK2): A New Target for the Treatment of Hematopoietic Neoplasms with TEL-FGFR3 Fusion or FGFR3 Active Mutation.

Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk

Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

A Prospective Study of t(4;14) Multiple Myeloma.

Proline-Rich Tyrosine Kinase-2 (PYK2): A New Target for the Treatment of Hematopoietic Neoplasms with TEL-FGFR3 Fusion or FGFR3 Active Mutation.

Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only